News
Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
COLUMBUS, June 09, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite...
Sermonix to Present Updated Data from ELAINE-2 Clinical Trial of Lasofoxifene in Combination with Abemaciclib in Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and an ESR1 Mutation after Progression on Prior Therapies at the 2022 ASCO Annual Meeting
COLUMBUS, Ohio, May 31, 2022 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Announces Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
COLUMBUS, Ohio, April 28, 2022 — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical...
Biotech raises $40M to test forgotten osteoporosis drug in treatment-resistant breast cancer
February 07, 2022 06:30am EST | Source: Sermonix Pharmaceuticals LLC A Columbus...
Sermonix Pharmaceuticals Announces Poster Presentation at the 2021 San Antonio Breast Cancer Symposium
Poster describes pre-clinical findings that lasofoxifene alone or in combination with a CDK...
Sermonix Pharmaceuticals Closes $40 Million Series A3 Financing Round Led by Perceptive Xontogeny Ventures Fund II
Funds will be used to further advance lasofoxifene through late-stage clinical development as a...
Sermonix Pharmaceuticals Completes Enrollment of Phase 2 Clinical Trial Collaboration Studying …
COLUMBUS, Ohio, June 28, 2021 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held...
Sermonix Pharmaceuticals Announces Breast Cancer Research Publication of Preclinical Lasofoxifene Study in Endocrine-Resistant Breast Cancer
Paper highlights the ability of lasofoxifene to inhibit primary tumor growth and reduce metastases...
To sign up for future Sermonix press releases, please enter your information below.